Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026)
Vivos Therapeutics' (VVOS) quarterly Short term Debt came in at $7.8 million in Q2 2026, up 4850.32% year-over-year from $157000.0 in Q2 2025, and up 6.48% quarter-over-quarter from $7.3 million in Q1 2026.
Powered by 
Analysis
Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Short term Debt for 5 consecutive years, with $7.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Short term Debt rose 4850.32% year-over-year to $7.8 million in Q2 2026; TTM through Jun 2026 was $7.8 million, a 4850.32% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, changed N/A from the prior year.
- Short term Debt was $7.8 million for Q2 2026 at Vivos Therapeutics, up from $7.3 million in the prior quarter.
- Over five years, Short term Debt peaked at $8.4 million in Q4 2025 and troughed at $157000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Align Technology | 11.30 Bn | 10.20 Bn | 757.43 Mn |
| 2 | Envista Holdings | 4.38 Bn | 3.26 Bn | 407.00 Mn |
| 3 | Dentsply Sirona | 2.27 Bn | 2.03 Bn | 493.00 Mn |
| 4 | Milestone Scientific | 37.81 Mn | 35.20 Mn | 1.56 Mn |
| 5 | Dror Ortho-Design | 9.77 Mn | 9.68 Mn | - |
| 6 | Vivos Therapeutics | 2.76 Mn | 790,007.20 | 2.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.77 Mn |
| Mar 31, 2026 | 7.30 Mn |
| Dec 31, 2025 | 8.35 Mn |
| Sep 30, 2025 | 339,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Dec 31, 2021 | 1.27 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 1.16 Mn |
| Dec 31, 2020 | 1.50 Mn |
| Dec 31, 2019 | 3.71 Mn |